within Pharmacolibrary.Drugs.ATC.N;

model N05BA14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.0005,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0011666666666666668,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05BA14</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pinazepam is a benzodiazepine derivative primarily used for its anxiolytic and sedative effects. It is indicated for the short-term treatment of anxiety and related disorders. Pinazepam is not widely approved or marketed today in most countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are not directly reported in the existing literature for healthy adult subjects; thus, the following are estimates based on known properties of oral benzodiazepines and available indirect data.</p><h4>References</h4><ol><li><p>Pacifici, GM, et al., &amp; Gomeni, R (1983). Pharmacokinetics of pinazepam in healthy volunteers. <i>International journal of clinical pharmacology research</i> 3(5) 331–337. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6147314/\">https://pubmed.ncbi.nlm.nih.gov/6147314</a></p></li><li><p>Pacifici, GM, et al., &amp; Placidi, GF (1982). Disposition, distribution, and liver first-pass effect of pinazepam in the rat. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 10(2) 180–182. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6124406/\">https://pubmed.ncbi.nlm.nih.gov/6124406</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05BA14;
